<DOC>
	<DOCNO>NCT01693081</DOCNO>
	<brief_summary>'Off period ' people Parkinson 's disease slow , stiff unable function disabling , treatment convert people `` '' , good , able function state would extremely useful . We assess safety , tolerability efficacy inhale dry powder apomorphine ( VR040 ) clinic-based study setting .</brief_summary>
	<brief_title>Phase IIa Multicentre Study Investigating VR040 Parkinson 's Disease</brief_title>
	<detailed_description>Background : 'Off ' period increase Parkinson 's disease progress benefit standard therapy wane . Subcutaneous apomorphine rescue 'off ' period , patient self-injection adverse cutaneous effect sometimes problematic . Methods : We assess safety , tolerability efficacy inhale dry powder apomorphine ( VR040 ) clinic-based Phase II study . Of 48 patient recruit 9 site , 47 randomize 2:1 inhaled apomorphine : placebo . Respirable dos ( drug predict reach lung ) ascend 1.5mg , 2.3mg , 3.0mg , 4.0mg efficacy achieve , administer patient practically define 'off ' state . The primary endpoint response unify Parkinson 's disease rating scale Part 3 ( UPDRS 3 ) , high dose receive patient . Secondary endpoint include time 'on ' , proportion patient convert 'off ' 'on ' , pharmacokinetics .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>1 . Male female 30 90 year old idiopathic PD least 5 year . 2 . Voluntary write informed consent provide . 3 . Willing able comply study procedure . 4 . Fulfilled step 1 2 UK Brain Bank Criteria . 5 . Classified Hoehn Yahr Stage II IV `` '' state . 6 . Motor fluctuation recognisable `` '' period control motor symptom , assess Motor Fluctuation Questionnaire . 7 . Optimised oral therapy . 8 . Dopaminergic responsiveness define ≥ 30 % improvement ( reduction ) UPDRS III score compare predose value . 1 . Participated trial investigational product within prior 3 month . 2 . Serious uncontrolled disease include serious psychological disorder . 3 . Previous intolerance apomorphine . 4 . Previous significant complication oral dopamine agonist therapy 5 . Women lactate , pregnant childbearing potential use reliable contraceptive method ( eg , barrier , intrauterine device , abstinence ) . 6 . Known HIV active chronic hepatitis B C infection . 7 . Any clinically significant abnormality follow review screen observation 8 . Patients , Investigator 's opinion , unsuitable study reason . 9 . Major ECG abnormality . 10 . Patients FEV1 ≤ 65 % predict . 11 . Patients show postural decrease systolic blood pressure ( BP ) ≥20 mm Hg show significant clinical symptom associate orthostatic hypotension . 12 . Patients persistent arterial hypotension , average systolic reading ≤110 mm Hg . 13 . Patients persistent elevation BP , average systolic reading ≥160 mm Hg . average diastolic reading ≥100 mm Hg . 14 . Patients take apomorphine time study visit , anabolic steroid , traditional antipsychotic ( unless low dose ) vasodilator treatment hypertension . The following atypical antipsychotic permit : Quetiapine ( include 50 mg per day ) , risperidone ( include 1 mg per day ) olanzapine ( include 2.5 mg per day ) . 15 . Patients take agent 5HT3 antagonist class include ondansetron , granisetron , dolasetron , palonosetron alosetron . 16 . Patients exist cancer remission le 5 year . 17 . Patients evidence ( ascertained examination , test history ) indicate cardiovascular , gastrointestinal tract , liver , kidney , central nervous system , pulmonary system bone marrow disorder Investigator 's opinion compromise patient safety . 18 . Patients known nonresponders apomorphine treatment `` '' episode ( eg , previous challenge test trial ) . 19 . Patients history drug alcohol abuse 12 month prior entry . 20 . Patients history clinically significant allergy VR040 formulation constituent ( include lactose opioids ) domperidone . 21 . Patients sign symptom suggestive psychosis , dementia , `` Parkinsonplus '' syndrome unstable systemic disease . 22 . Patients history stroke , seizure neurological condition . 23 . Patients dyskinesia rat 4 Item 32 UPDRS IV assessment Screening ( dyskinesia present ≥76 % wake day ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>inhaled apomorphine</keyword>
	<keyword>convert `` '' `` ''</keyword>
</DOC>